Sanofi-Aventis announced recently the results of a study that demonstrated that patients using Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus patients treated with premix analog insulin. Related terms:glargine glulisinedavidson glulisineGlulisine Glargineglulisine to glargineinsulin glargine rdna origin […]